TABLE 3.
Adjusted Baseline Characteristics After Propensity Matching
| Variable | Preoperative (n = 696) | No preoperative RT (n = 1392) | P |
|---|---|---|---|
| Patient characteristics | |||
| Age, yr (IQR) | 58 (47–68) | 59 (47–68) | 0.394 |
| Female | 307 (44.1%) | 609 (43.8%) | 0.913 |
| Race | 0.464 | ||
| White | 598 (87.7%) | 1,171 (86%) | |
| Black | 63 (9.2%) | 150 (11%) | |
| Other | 21 (3.1%) | 41 (3%) | |
| Charlson Comorbidity score | 0.407 | ||
| 0 | 436 (83.2%) | 880 (84.2%) | |
| 1 | 73 (13.9%) | 146 (14%) | |
| ≥2 | 15 (2.9%) | 19 (1.8%) | |
| Education above median | 401 (61.9%) | 788 (61.2%) | 0.818 |
| Income above median | 435 (67.1%) | 851 (66.1%) | 0.695 |
| Distance to cancer center (IQR) | 26 (8–84) | 17 (6–50) | 0.294 |
| Treatment facility | 0.534 | ||
| Community Cancer Program | 14 (2%) | 22 (1.6%) | |
| Comprehensive Community Cancer Program | 183 (26.6%) | 392 (28.5%) | |
| Academic/Research Program | 491 (71.4%) | 960 (69.9%) | |
| Insurance | 0.418 | ||
| Private | 357 (55.5%) | 725 (54.7%) | |
| Medicare | 208 (32.3%) | 439 (33.1%) | |
| Medicaid | 33 (5.1%) | 89 (6.7%) | |
| Government | 15 (2.3%) | 21 (1.6%) | |
| Uninsured | 30 (4.7%) | 51 (3.8%) | |
| Tumor characteristics | |||
| Tumor size (mm) | 115 (78–170) | 110 (70–160) | 0.721 |
| Tumor size | 0.549 | ||
| <5 cm | 50 (8.1%) | 88 (7.1%) | |
| 5–9.9 cm | 182 (29.4%) | 399 (32.1%) | |
| 10.0–19.9 cm | 292 (47.1%) | 581 (46.7%) | |
| >20.0 cm | 96 (15.5%) | 175 (14.1%) | |
| Grade | 0.996 | ||
| Well differentiated | 90 (15.3%) | 184 (15.7%) | |
| Moderately differentiated | 83 (14.1%) | 164 (14%) | |
| Poorly differentiated | 229 (39%) | 453 (38.6%) | |
| Undifferentiated/anaplastic | 185 (31.5%) | 373 (31.8%) | |
| Histology | 0.955 | ||
| Dedifferentiated liposarcoma | 40 (5.7%) | 74 (5.3%) | |
| Epithelioid sarcoma | 11 (1.6%) | 19 (1.4%) | |
| Fibrosarcoma NOS | 14 (2%) | 43 (3.1%) | |
| Giant cell sarcoma | 79 (11.4%) | 151 (10.8%) | |
| Hemangiosarcoma | 5 (0.7%) | 9 (0.6%) | |
| Leiomyosarcoma | 162 (23.3%) | 305 (21.9%) | |
| Liposarcoma (well differentiated) | 47 (6.8%) | 91 (6.5%) | |
| Malignant fibrous histiocytoma | 90 (12.9%) | 211 (15.2%) | |
| MPNST | 21 (3%) | 45 (3.2%) | |
| Myxoid liposarcoma | 59 (8.5%) | 122 (8.8%) | |
| Pleomorphic liposarcoma | 27 (3.9%) | 58 (4.2%) | |
| Sarcoma NOS | 87 (12.5%) | 166 (11.9%) | |
| Spindle cell sarcoma | 54 (7.8%) | 98 (7%) | |
| Treatment specifics | |||
| Neoadjuvant RT | 696 (100%) | 0 (0%) | <0.001 |
| Neoadjuvant chemo | 95 (25.3%) | 24 (3.9%) | <0.001 |
| Surgery type | 0.991 | ||
| 1: Excision | 536 (77%) | 1080 (77.6%) | |
| 2: Complete resection | 38 (5.5%) | 73 (5.2%) | |
| 3: Resection with debulking | 28 (4%) | 56 (4%) | |
| 4: Radical resection | 94 (13.5%) | 183 (13.1%) | |
IQR indicates interquartile range; MPNST, malignant peripheral nerve sheath tumors; NOS, not otherwise specified.